- Home
- TZUP vs IMUX Comparison
TZUP vs IMUX Comparison
Compare TZUP & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TZUP
- IMUX
- Stock Information
- Founded
- TZUP 2020
- IMUX 2016
- Country
- TZUP United States
- IMUX United States
- Employees
- TZUP N/A
- IMUX N/A
- Industry
- TZUP
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- TZUP
- IMUX Health Care
- Exchange
- TZUP NYSE
- IMUX Nasdaq
- Market Cap
- TZUP 66.7M
- IMUX 67.8M
- IPO Year
- TZUP N/A
- IMUX N/A
- Fundamental
- Price
- TZUP $12.67
- IMUX $0.83
- Analyst Decision
- TZUP
- IMUX Strong Buy
- Analyst Count
- TZUP 0
- IMUX 6
- Target Price
- TZUP N/A
- IMUX $11.60
- AVG Volume (30 Days)
- TZUP 376.1K
- IMUX 1.6M
- Earning Date
- TZUP 08-11-2025
- IMUX 08-07-2025
- Dividend Yield
- TZUP N/A
- IMUX N/A
- EPS Growth
- TZUP N/A
- IMUX N/A
- EPS
- TZUP N/A
- IMUX N/A
- Revenue
- TZUP $487.00
- IMUX N/A
- Revenue This Year
- TZUP N/A
- IMUX N/A
- Revenue Next Year
- TZUP N/A
- IMUX N/A
- P/E Ratio
- TZUP N/A
- IMUX N/A
- Revenue Growth
- TZUP N/A
- IMUX N/A
- 52 Week Low
- TZUP $2.02
- IMUX $0.56
- 52 Week High
- TZUP $13.44
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- TZUP N/A
- IMUX 55.91
- Support Level
- TZUP N/A
- IMUX $0.68
- Resistance Level
- TZUP N/A
- IMUX $0.83
- Average True Range (ATR)
- TZUP 0.00
- IMUX 0.05
- MACD
- TZUP 0.00
- IMUX 0.02
- Stochastic Oscillator
- TZUP 0.00
- IMUX 88.50
About TZUP THUMZUP MEDIA CORP
Thumzup Media Corp operates in the social media branding and marketing industry. The company operates in a single business segment which is social media marketing. The Thumzup App works on both iPhone and Android mobile operating systems and connects brands and people who use and love these brands. The easy-to-use dashboard allows advertisers to programmatically customize their campaigns. Cash payments are made to App users/creators through Venmo and PayPal.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.